PharmacoEconomics

Bridging Decision Analytic Modelling with a Cross-Sectional Study: Application to Parkinson's Disease
pp. 227-236(10)
Author: Nuijten M.J.C.

ACE Inhibitors after Myocardial Infarction: Clinical and Economic Considerations
pp. 237-243(7)
Author: Davie A.P.

Clinical and Economic Factors Important to Anaesthetic Choice for Day-Case Surgery
pp. 245-262(18)
Authors: Eger E.I.; White P.F.; Bogetz M.S.

Evaluating the Potential ‘Economic Attractiveness’ of New Therapies in Patients with Non-ST Elevation Acute Coronary Syndrome
pp. 263-272(10)
Authors: Eisenstein E.L.; Peterson E.D.; Jollis J.G.; Tardiff B.E.; Califf R.M.; Knight J.D.; Mark D.B.

Assessing Health Utilities in Schizophrenia: A Feasibility Study
pp. 273-286(14)
Authors: Voruganti L.N.; Awad A.G.; Oyewumi L.K.; Cortese L.; Zirul S.; Dhawan R.

Economics of the Antithymocyte Globulins Thymoglobulin and Atgam in the Treatment of Acute Renal Transplant Rejection
pp. 287-293(7)
Authors: Schnitzler M.A.; Woodward R.S.; Lowell J.A.; Amir L.; Schroeder T.J.; Singer G.G.; Brennan D.C.

The Cost Effectiveness of Misoprostol Prophylaxis Alongside Long Term Nonsteroidal Anti-Inflammatory Drugs: Implications of the MUCOSA Trial
pp. 295-304(10)
Authors: Davey P.J.; Meyer E.

Household Income Losses Associated With Ischaemic Heart Disease For US Employees
pp. 304-314(11)
Authors: Herrin J.; Cangialose C.B.; Boccuzzi S.J.; Weintraub W.S.; Ballard D.J.